Literature DB >> 33403026

N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer.

Qunying Wu1, Xing Xie2, Yiming Huang3, Shanshan Meng2, Youcheng Li4, Huifeng Wang1, Yanling Hu3.   

Abstract

Prostate cancer (PCa) is one of the most common epithelial malignant tumors and the fifth leading cause of cancer death in men. An increasing number of studies have demonstrated that N6-methyladenosine (m6A) plays a crucial role in tumorigenesis and tumor development. However, little is known about the role and levels of common m6A regulators and m6A levels in PCa. In this study, we analyzed the characteristic expression of m6A regulators in PCa and castration-resistant prostate cancer (CRPC). UALCAN and cBioPortal were used to estimate the clinical value and genetic alterations of m6A regulators, respectively. The correlation between m6A regulators and androgen receptor (AR) was assessed using Gene Expression Profiling Interactive Analysis (GEPIA) by Pearson correlation statistics. Total m6A levels were detected in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice and PCa cell lines. Results showed that the expression of methyltransferase-like 3 (METTL3) and YTH domain family members, namely, YTHDC2, YTHDF1, and YTHDF2 were generally upregulated in PCa, whereas those of fat mass and obesity-associated protein (FTO), AlkB homolog 5 (ALKBH5), and methyltransferase-like 14 (METTL14) were downregulated. The expression of METTL3, METTL14, Wilms' tumor 1-associating protein (WTAP), YTHDC2, YTHDF1, and YTHDF2 were remarkably higher in CRPC with lymph node metastasis than that in CRPC with bone metastasis, whereas ALKBH5, FTO, and YTHDF3 significantly decreased in CRPC with lymph node metastasis tissues. YTHDF1, YTHDF2, and YTHDC2 were positively correlated with the Gleason grades of PCa, and METTL14, FTO, and ALKBH5 were negatively associated with the Gleason classification. M6A regulators were positively correlated with AR. Patients with a genomic alteration of m6A were associated with poor disease-free survival (DFS). The total m6A levels in TRAMP mice increased dramatically compared with those in tumor-free mice, and m6A levels in LNCaP cell lines were higher than DU145 and PC3 cell lines. In summary, METTL3, METTL14, ALKBH5, FTO, YTHDC2, YTHDF1, and YTHDF2 were abnormally expressed in PCa and related to Gleason classification. Changes in m6A levels maybe contributed to the development and progression of PCa. © The author(s).

Entities:  

Keywords:  N6-methyladenosine; androgen receptor; castration-resistant prostate cancer; prostate cancer; tumorigenesis and progression

Year:  2021        PMID: 33403026      PMCID: PMC7778550          DOI: 10.7150/jca.46379

Source DB:  PubMed          Journal:  J Cancer        ISSN: 1837-9664            Impact factor:   4.207


  39 in total

1.  Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.

Authors:  Daniel R Rhodes; Shanker Kalyana-Sundaram; Vasudeva Mahavisno; Radhika Varambally; Jianjun Yu; Benjamin B Briggs; Terrence R Barrette; Matthew J Anstet; Colleen Kincead-Beal; Prakash Kulkarni; Sooryanaryana Varambally; Debashis Ghosh; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

2.  Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality.

Authors:  Derya Tilki; Ming-Hui Chen; Jing Wu; Hartwig Huland; Markus Graefen; Michelle Braccioforte; Brian J Moran; Anthony V D'Amico
Journal:  JAMA Oncol       Date:  2019-02-01       Impact factor: 31.777

Review 3.  m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer.

Authors:  Huilin Huang; Hengyou Weng; Jianjun Chen
Journal:  Cancer Cell       Date:  2020-03-16       Impact factor: 31.743

4.  m6A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program.

Authors:  Sicong Zhang; Boxuan Simen Zhao; Aidong Zhou; Kangyu Lin; Shaoping Zheng; Zhike Lu; Yaohui Chen; Erik P Sulman; Keping Xie; Oliver Bögler; Sadhan Majumder; Chuan He; Suyun Huang
Journal:  Cancer Cell       Date:  2017-03-23       Impact factor: 31.743

5.  Integrative clinical genomics of advanced prostate cancer.

Authors:  Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

6.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses.

Authors:  Darshan S Chandrashekar; Bhuwan Bashel; Sai Akshaya Hodigere Balasubramanya; Chad J Creighton; Israel Ponce-Rodriguez; Balabhadrapatruni V S K Chakravarthi; Sooryanarayana Varambally
Journal:  Neoplasia       Date:  2017-07-18       Impact factor: 5.715

7.  m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade.

Authors:  Seungwon Yang; Jiangbo Wei; Yan-Hong Cui; Gayoung Park; Palak Shah; Yu Deng; Andrew E Aplin; Zhike Lu; Seungmin Hwang; Chuan He; Yu-Ying He
Journal:  Nat Commun       Date:  2019-06-25       Impact factor: 14.919

8.  EBV epitranscriptome reprogramming by METTL14 is critical for viral-associated tumorigenesis.

Authors:  Fengchao Lang; Rajnish Kumar Singh; Yonggang Pei; Shengwei Zhang; Kunfeng Sun; Erle S Robertson
Journal:  PLoS Pathog       Date:  2019-06-21       Impact factor: 6.823

9.  RNA m6A Methyltransferase METTL3 Promotes The Growth Of Prostate Cancer By Regulating Hedgehog Pathway.

Authors:  Jiarong Cai; Fei Yang; Hailun Zhan; Jie Situ; Wenbiao Li; Yunhua Mao; Yun Luo
Journal:  Onco Targets Ther       Date:  2019-11-05       Impact factor: 4.147

Review 10.  YTH Domain: A Family of N6-methyladenosine (m6A) Readers.

Authors:  Shanhui Liao; Hongbin Sun; Chao Xu
Journal:  Genomics Proteomics Bioinformatics       Date:  2018-04-30       Impact factor: 7.691

View more
  12 in total

1.  RNA m6A Methylation Regulators Multi-Omics Analysis in Prostate Cancer.

Authors:  Hao Su; Yutao Wang; Hongjun Li
Journal:  Front Genet       Date:  2021-11-26       Impact factor: 4.599

Review 2.  Epigenetic and Epitranscriptomic Control in Prostate Cancer.

Authors:  Judith López; Ana M Añazco-Guenkova; Óscar Monteagudo-García; Sandra Blanco
Journal:  Genes (Basel)       Date:  2022-02-18       Impact factor: 4.096

3.  Demethyltransferase FTO alpha-ketoglutarate dependent dioxygenase (FTO) regulates the proliferation, migration, invasion and tumor growth of prostate cancer by modulating the expression of melanocortin 4 receptor (MC4R).

Authors:  Sheng Li; Lin Cao
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

4.  Circular RNA midline-1 (circMID1) promotes proliferation, migration, invasion and glycolysis in prostate cancer.

Authors:  Yafei Ding; Mi Wang; Jinjian Yang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

5.  YTHDF1 promotes the proliferation, migration, and invasion of prostate cancer cells by regulating TRIM44.

Authors:  Weijian Li; Gaohuang Chen; Zhenyu Feng; Baoyi Zhu; Lilin Zhou; Yuying Zhang; Junyan Mai; Chonghe Jiang; Jianwen Zeng
Journal:  Genes Genomics       Date:  2021-10-22       Impact factor: 1.839

6.  Construction of a Comprehensive Diagnostic Scoring Model for Prostate Cancer Based on a Novel Six-Gene Panel.

Authors:  Yunfeng Liu; Simei Qiu; Dongshan Sun; Ting Xiong; Qiuling Xiang; Quhuan Li
Journal:  Front Genet       Date:  2022-04-26       Impact factor: 4.772

7.  m6A Methylation Regulators Are Predictive Biomarkers for Tumour Metastasis in Prostate Cancer.

Authors:  Yingchun Liang; Xiaohua Zhang; Chenkai Ma; Jimeng Hu
Journal:  Cancers (Basel)       Date:  2022-08-21       Impact factor: 6.575

Review 8.  Functions and mechanisms of N6‑methyladenosine in prostate cancer (Review).

Authors:  Hongyuan Wan; Yanyan Feng; Junjie Wu; Lijie Zhu; Yuanyuan Mi
Journal:  Mol Med Rep       Date:  2022-07-20       Impact factor: 3.423

9.  Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation.

Authors:  Yongjun Quan; Xiaodong Zhang; Hao Ping
Journal:  Cancer Cell Int       Date:  2022-01-19       Impact factor: 5.722

Review 10.  Functions, mechanisms, and therapeutic implications of METTL14 in human cancer.

Authors:  Qian Guan; Huiran Lin; Lei Miao; Huiqin Guo; Yongping Chen; Zhenjian Zhuo; Jing He
Journal:  J Hematol Oncol       Date:  2022-02-03       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.